Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Acq. announced Quarterly results
|
PTC THERAPEUTICS, INC. (PTCT)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
09/28/2023 |
8-K
| Quarterly results |
08/03/2023 |
8-K
| Quarterly results |
07/19/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
07/17/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
06/06/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
05/23/2023 |
8-K
| Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm... |
05/17/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
04/27/2023 |
8-K
| Quarterly results |
04/18/2023 |
8-K
| Quarterly results |
03/24/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs:
|
"Non-Disparagement. To the extent permitted by law, Executive understands and agrees that as a condition for payments and benefits under this Agreement, for a period of five years following the date hereof Executive shall not make any false, disparaging or derogatory statements to any person or entity, including any media outlet, regarding the Company or any of its directors, officers, employees, agents or representatives or about the Company’ s business affairs and financial condition. Executive further agrees that as a condition for payments and benefits under this Agreement any statements made by Executive regarding the Company shall be consistent in tenor, tone and content with the statements made in the press release filed by the Company on or around the date hereof announcing Executiv...",
"Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics" |
|
01/09/2023 |
8-K
| Quarterly results |
12/06/2022 |
8-K
| Quarterly results |
10/27/2022 |
8-K
| Quarterly results |
10/27/2022 |
8-K
| Quarterly results |
10/18/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
09/07/2022 |
8-K
| Investor presentation |
08/15/2022 |
8-K
| Quarterly results |
08/04/2022 |
8-K
| Quarterly results |
06/21/2022 |
8-K
| Quarterly results |
06/09/2022 |
8-K
| Quarterly results |
05/27/2022 |
8-K
| Quarterly results |
05/03/2022 |
8-K
| Quarterly results |
02/22/2022 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I... |
01/10/2022 |
8-K
| Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment... |
11/30/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
10/28/2021 |
8-K
| Quarterly results |
09/23/2021 |
8-K
| Quarterly results |
07/29/2021 |
8-K
| Quarterly results |
06/09/2021 |
8-K
| Quarterly results |
05/04/2021 |
8-K
| Quarterly results |
04/15/2021 |
8-K
| Quarterly results |
02/25/2021 |
8-K
| Quarterly results |
02/04/2021 |
8-K
| Quarterly results |
01/11/2021 |
8-K
| Quarterly results |
|
|
|